Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Millennium Management Llc Sells 8,151 Shares

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc sold 8,151 shares of the stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $31.01, for a total transaction of $252,762.51. Following the completion of the sale, the insider owned 133,986 shares of the company’s stock, valued at approximately $4,154,905.86. The trade was a 5.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $28.12, for a total transaction of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.81, for a total transaction of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $26.61, for a total transaction of $23,629.68.
• On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc bought 5,731 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $25.49, for a total transaction of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $31.65, for a total transaction of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $34.49 per share, for a total transaction of $212,975.75.
• On Tuesday, March 31st, Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock. The shares were acquired at an average price of $28.16 per share, for a total transaction of $169,100.80.

Sensei Biotherapeutics Trading Up 3.1%

Sensei Biotherapeutics stock opened at $20.43 on Friday. The company has a market capitalization of $27.38 million, a P/E ratio of -1.23 and a beta of -0.18. The firm’s fifty day simple moving average is $28.89 and its 200-day simple moving average is $17.87. Sensei Biotherapeutics, Inc. has a 1-year low of $5.25 and a 1-year high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83). On average, equities research analysts predict that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current year.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Ratings Changes

A number of research analysts have recently weighed in on SNSE shares. Leerink Partners started coverage on shares of Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Friday, April 24th. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $40.00.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the period. Renaissance Technologies LLC owned about 2.39% of Sensei Biotherapeutics worth $1,010,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.